INSILICO (03696.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 55.45

From 52W high−20.88%

Volume48.90M

Market capHKD 35.20B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 55.45

From 52W high

−20.88%

Volume

48.90M

Market cap

HKD 35.20B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

70.2

MomentumView details →

1D Return

+13.12%

YTD Return

+63.35%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+13.12%

YTD Return

+63.35%

1Y Return

—

RSI (14)

70.2

vs 50D SMA

+30.89%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.06

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Insilico Medicine signed new out-licensing deals worth US$7.3 billion in H1 2026, bringing cumulative out-licensing deal value to US$11 billion, with partners including Eli Lilly, Takeda, Servier, Sanofi, SK Biopharmaceuticals, China Medical System, Qilu and Tenacia.2d ago

Insilico Medicine signed a strategic cooperation agreement with Mobius Biomedical to collaborate on single-cell data production and integration for AI model training.12d ago

Similar companies

Plantynet Co., Ltd.075130.KQ Zscaler, Inc.ZS Secuve Co., Ltd.131090.KQ Okta, Inc.OKTA MongoDB, Inc.MDB CoreWeave, Inc. Class A Common StockCRWV Find similar companies →

Latest newsMore news →

Insilico Medicine signed new out-licensing deals worth US$7.3 billion in H1 2026, bringing cumulative out-licensing deal value to US$11 billion, with partners including Eli Lilly, Takeda, Servier, Sanofi, SK Biopharmaceuticals, China Medical System, Qilu and Tenacia.2d ago Insilico Medicine signed a strategic cooperation agreement with Mobius Biomedical to collaborate on single-cell data production and integration for AI model training.12d ago